Asset Details
Do you wish to reserve the book?
A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
Do you wish to request the book?
A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
2014
Overview
Gonadotropins extracted from the urine of post-menopausal women have traditionally been used to stimulate folliculogenesis in the treatment of infertility and in assisted reproductive technology (ART). Products, such as human menopausal gonadotropin (hMG), consist not only of a mixture of the hormones, follicle-stimulating hormone (FSH), luteinising hormone (LH) and human chorionic gonadotropin (hCG), but also other biologically active contaminants, such as growth factors, binding proteins and prion proteins. The actual amount of molecular LH in hMG preparations varies considerably due to the purification process, thus hCG, mimicking LH action, is added to standardise the product. However, unlike LH, hCG plays a different role during the natural human menstrual cycle. It is secreted by the embryo and placenta, and its main role is to support implantation and pregnancy. More recently, recombinant gonadotropins (r-hFSH and r-hLH) have become available for ART therapies. Recombinant LH contains only LH molecules. In the field of reproduction there has been controversy in recent years over whether r-hLH or hCG should be used for ART. This review examines the existing evidence for molecular and functional differences between LH and hCG and assesses the clinical implications of hCG-supplemented urinary therapy compared with recombinant therapies used for ART.
Publisher
BioMed Central,BioMed Central Ltd
Subject
/ Chorionic Gonadotropin - adverse effects
/ Chorionic Gonadotropin - chemistry
/ Chorionic Gonadotropin - genetics
/ Chorionic Gonadotropin - pharmacology
/ Drug Contamination - prevention & control
/ Female
/ Fertility Agents, Female - adverse effects
/ Fertility Agents, Female - chemistry
/ Fertility Agents, Female - pharmacology
/ Hormones
/ Humans
/ Infertility, Female - therapy
/ Luteinizing Hormone - adverse effects
/ Luteinizing Hormone - chemistry
/ Luteinizing Hormone - genetics
/ Luteinizing Hormone - pharmacology
/ Medicine
/ Patients
/ Proteins
/ Recombinant Proteins - adverse effects
/ Recombinant Proteins - chemistry
/ Recombinant Proteins - pharmacology
/ Reproductive Techniques, Assisted
/ Review
/ Urine
